Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NEXI | US
-0.08
-23.82%
Healthcare
Biotechnology
30/06/2024
21/10/2024
0.25
0.23
0.34
0.22
NexImmune Inc. a clinical-stage biotechnology company engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation a nanoparticle technology platform. The company's product candidates include NEXI-001 an allogeneic cell therapy which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002 an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003 a candidate targeted against HPV-associated malignancies which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg Maryland.
View LessValue Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
281.1%1 month
239.4%3 months
194.6%6 months
181.9%-
-
0.41
-
-
0.53
-
-
-16.38M
350.62K
350.62K
-
-
-
-
-232.97
2.26
1.30
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.15
Range1M
0.16
Range3M
1.68
Rel. volume
0.94
Price X volume
1.38K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Vaxxinity Inc. Class A Common Stock | VAXX | Biotechnology | 0.002 | 253.57K | 0.00% | n/a | 113.12% |
Navidea Biopharmaceuticals Inc | NAVB | Biotechnology | 0.001 | 100.08K | 0.00% | n/a | -38.49% |
U.S. Stem Cell Inc | USRM | Biotechnology | 0.0001 | 64.15K | 0.00% | n/a | -60.68% |
EFTR | EFTR | Biotechnology | 0.0012 | 5.64K | 0.00% | n/a | 2315.36% |
Calithera Biosciences Inc | CALA | Biotechnology | 0.001 | 4.87K | -50.00% | n/a | 8.17% |
OCEAW | OCEAW | Biotechnology | 0.0398 | 0 | 2.58% | n/a | -16.02% |
Nutriband Inc. Warrant | NTRBW | Biotechnology | 1.15 | 0 | 9.52% | n/a | 1.72% |
NKGen Biotech Inc. Warrants | NKGNW | Biotechnology | 0.032 | 0 | 29.03% | n/a | -40.33% |
JSPRW | JSPRW | Biotechnology | 0.21 | 0 | 0.00% | n/a | 2.31% |
ICUCW | ICUCW | Biotechnology | 0.039 | 0 | 0.52% | n/a | -45.50% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
No data |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.53 | 0.53 | Par |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 0.41 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 194.58 | 72.80 | Riskier |
Debt to Equity | - | -1.23 | - |
Debt to Assets | - | 0.25 | - |
Market Cap | 350.62K | 3.66B | Emerging |